What is endobarrier™?
The EndoBarrier is a medical device for the treatment of type 2 diabetes and obesity which is worn inside of the body. The endobarrier™ is a piece of sophisticated- clinical grade plastic tubing which coats the lining of the stomach and intestine. The tubing is placed along the GI tract endoscopically (via the mouth) to create a barrier between food and the wall of the intestine and to delay the mixing of digestive enzymes with the food.
What is involved in surgery?
The patient is put under anaesthetic and the thin plastic tube is inserted through the mouth and stomach and down into the top 2 ft of the small intestine, where it is fixed in place by a sprung metal anchor.
How does it work?
Placing the tube here means food cannot be as easily digested through the walls of the intestine so less fat, sugar and salt than normal is taken in. Food has to be absorbed further down the intestine. The body reacts to food in a different way when the first part of the small intestine is blocked, the barrier delays absorption and alters the activation of hormonal signals that originate in the intestine. This gives a similar effect as a gastric bypass, but without the surgery and without changing the anatomy of the stomach, thereby avoiding many of the risks. 1,2
Who is this suitable for?
Treatment options should always be discussed with your consultant but the Endobarrier may be particularly helpful for individuals with Type 2 diabetes who are unlikely to be able to cope with the trauma of gastric surgery.
The endobarrier™ gastrointestinal liner is designed to help patients regain metabolic control of Type 2 Diabetes and to aid weight loss. EndoBarrier™ has the potential to dramatically change the treatment approach for people who are obese or have Type 2 Diabetes. Clinical experience1,2 has found that EndoBarrier™ can provide immediate relief from Type 2 Diabetes in patients. In addition, most patients experience clinically significant weight loss 1,2. This is believed to have a long term effect in managing insulin resistance as well as a positive impact on cardiovascular risk factors, including elevated lipid levels and high blood pressure. 1,2.
1. Moura, GHD, et al, One Year Results of an Endoscopic, Duodenal-Jejunal Exclusion Device for Weight Loss and Control of Type 2 Diabetes. Hospital das Clinicas, University of São Paulo, São Paulo, Brazil. DT&T, February 2012, vol 14, no.2:183-189.
2. Escalona, A., et al,“Post-explant follow-up after 12 months implantation of an endoscopic duodenal-jejunal bypass liner.”Department of Digestive Surgery.”Faculty of Medicine Pontificia Universidad Católica de Chile. Annals of Surgery, June 2012 ,Vol 255, Issue 6, p 1080–1085